EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

A Multigene Assay for Predicting the Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer



A Multigene Assay for Predicting the Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer



Breast Diseases: A Year Book Quarterly 16(3): 219-220




(PDF emailed within 0-6 h: $19.90)

Accession: 063334047

Download citation: RISBibTeXText

DOI: 10.1016/S1043-321X(05)80168-7



Related references

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New England Journal of Medicine 351(27): 2817-2826, 2004

Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. Journal of Clinical Oncology 28(11): 1829-1834, 2010

Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients NSABP studies B-20 and B-14. Breast Cancer Research & Treatment 82(Supplement 1): S10-S11, 2003

Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer. Journal of Clinical Oncology 23(16_suppl): 510-510, 2016

Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients M D Anderson Clinical Validation Study. Breast Cancer Research & Treatment 82(Supplement 1): S11, 2003

Establishment of a risk scoring system for predicting locoregional recurrence in T1 to T2 node-negative breast cancer patients treated with mastectomy: Implications for postoperative radiotherapy. Medicine 96(26): E7343-E7343, 2017

Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer. Breast Cancer Research and Treatment 133(3): 1115-1123, 2012

Predicting recurrence in axillary-node negative breast cancer patients. Breast Cancer Research & Treatment 25(2): 127-139, 1993

DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group. European Journal of Cancer 43(11): 1679-1686, 2007

Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clinical Cancer Research 11(9): 3315-3319, 2005

Predicting recurrence in axillary node negative breast cancer patients 10 year follow up results. Proceedings of the American Association for Cancer Research Annual Meeting 33: 212, 1992

Predicting recurrence in axillary node negative breast cancer patients using adaptive artificial intelligence. Breast Cancer Research & Treatment 16(2): 190, 1990

Affinity Biosensors for Detection of Mycotoxins in Food. Advances in Food and Nutrition Research 85: 263-310, 2018

Clinical recognition and management of depression in node negative breast cancer patients treated with tamoxifen. Breast Cancer Research & Treatment. 27(3): 277-281, 1993

Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. Journal of Clinical Oncology 27(15): 2466-2473, 2009